TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06714149

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoreactivity testing
Description: Blood samples will be collected and used to determine the intensity of the allergenicity of the subject toward different types of pollen. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoreactivity testing (negative control)
Description: Blood samples will be collected and used to determine the background activity of our immunoreactivity tests. The investigators will use samples from negative controls to demonstrate that non-allergic individuals do not react to our assays, confirming that our pollen extracts have no background reactivity. This will be done by the detection of sIgE antibodies to the pollen extracts and basophil activation testing (BAT) with pollen extracts.
Study: NCT06711783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family based therapy
Description: Family based therapy following the Maudsley model
Study: NCT06714227

Intervention type: GENETIC
Intervention: Molecular analysis of genomic DNA (exome sequencing) from peripheral blood sample
Description: The first level of investigation will focus on genes already described in cases of pathogenic germline variants of prostate cancer and/or DNA repair system genes. The second level of investigation will consider variants in genes known to confer increased risk of cancer development, e.g., genes listed in the UK health system's solid tumor predisposition gene panel. Finally, pathogenic/probably pathogenic variants in the exome in genes attributable to increased risk will be evaluated on the basis of molecular pathway and findings in the scientific literature.
Study: NCT06713447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTI164
Description: This intervention uses Full-Spectrum Medicinal Cannabis Plant Extract with a low THC concentration of 0.08% (NTI164) specifically formulated to target inflammation in various neurological conditions. The dose of 20mg/kg has been selected based off existing clinical trial evidence for NTI164, and is similar to the dose of other cannabis-based drugs used in neurology. The safety of NTI164 has been rigorously tested in several ongoing paediatric clinical trials through blood tests and clinician-rated surveys.
Study: NCT06714669

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Control Group (Propofol Anesthesia Arm):~Patients in this arm will receive Propofol as the primary anesthetic agent for general anesthesia. Propofol is a well-established anesthetic drug commonly used in clinical practice for its rapid onset and short duration of action. Similar to the experimental group, the dosing regimen and administration protocol for Propofol will be tailored to the individual patient's needs and the surgical procedure. Hemodynamic stability and other vital signs will also be closely monitored in this group to assess the safety and effectiveness of Propofol in comparison to Remimazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Experimental Group (Remimazolam Anesthesia Arm):~Patients in this arm will receive Remimazolam as the primary anesthetic agent for inducing and maintaining general anesthesia. Remimazolam belongs to a new class of benzodiazepines and acts by enhancing the activity of GABAA receptors, leading to sedation and anesthesia. The specific dosing regimen and administration protocol for Remimazolam will be determined based on the patient's characteristics and the surgical procedure being performed. Close monitoring of the patient's vital signs, particularly hemodynamic parameters, will be conducted throughout the anesthesia period to ensure safety and efficacy.
Study: NCT06713174

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assessment of Interleukin 8 and 10 Level Changes Before and During Root Canal Treatment for Necrotic Pulp with Apical Periodontitis
Description: This study will be performed to investigate interleukin-8 (IL-8) and interleukin-10 (IL-10) level changes in gingival crevicular fluid (GCF) and periapical fluid before and during root canal treatment (RCT) in patients with necrotic pulp and apical periodontitis. The null hypothesis tested will be There is no significant difference in (IL-8) and (IL-10) levels in gingival crevicular fluid (GCF) and periapical before and during root canal treatment (RCT) for necrotic pulp with apical periodontitis.
Study: NCT06713109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interview techniques
Description: Motivational interviews will be conducted 4 times. As a result of these interviews, the breastfeeding problem or anxiety in the mother will be evaluated and the effectiveness of the interview will be solved.
Study: NCT06137469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/SHR20004
Description: SHR20004 was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study: NCT06589674

Intervention type: DIAGNOSTIC_TEST
Intervention: Pulse variability index measurement
Description: Peripheral perfusion index (PI) is an easy-to-implement and low-cost monitoring procedure obtained by interpreting non-invasive data obtained from pulse oximetry via plethysmography. It is a tool that allows interpretation of fluid status through changes in pulse oximetry waves caused by respiration. High perfusion indices are interpreted as low arterial tone. Changes in perfusion index are interpreted as indicators of vascular tone or fluid deficit problems in patients. The ratio of the highest and lowest PI values gives the Pleth Variability Index (PVI) (3,4). Hypotension can be predicted during anesthesia induction with PVI

Intervention type: OTHER
Intervention: Diastolic shock index
Description: The Diastolic Shock Index (DSI) is a hemodynamic parameter calculated by dividing the heart rate (HR) by the diastolic blood pressure (DBP). It reflects the balance between cardiac output and systemic vascular resistance, particularly in critically ill patients. A higher DSI can indicate impaired vascular resistance and may be useful for predicting the need for vasopressor support, especially in conditions like septic shock. However, its application in predicting hypotension during anesthesia induction is still under investigation.
Study: NCT06586528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NGAGE tool
Description: Access to NGAGE tool
Study: NCT06669676

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: patients will be given acupuncture in addition to standard medical treatment to prevent ponv

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No acupuncture
Description: patients will be given standard medical treatment to prevent ponv
Study: NCT04821622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talazoparib plus enzalutamide
Description: experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo plus enzalutamide
Description: Active comparator arm
Study: NCT06250283

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Resveratrol (500 mg)
Study: NCT06137469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen/Placebo
Description: Placebo was administered by titration, with all subjects starting on Day 4 with an initial dose of 0.03 mg/d of SHR20004 or placebo, with the dose being increased by 0.03 mg/d per week. The dose was increased to 0.15 mg/d and then maintained for 5 days.
Study: NCT06250283

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (500 mg)
Study: NCT05316285

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga exercise
Description: Yoga lesson practices will be designed and implemented by instructors physiotherapists who have completed 200 hours of yoga instructor training (RYT-200). The yoga program, which will consist of one-hour sessions once a week, is planned to last 14 weeks. 4 weeks of classes will be theoretical lessons related to yoga philosophy, 10 weeks of yoga sessions will be applied every week on different concepts such as upper extremity and / or lower extremity focused strengthening and / or flexibility and breathing exercises. In addition to this training, students will be advised to repeat the practices once a week. Sessions will begin with breathing practices called pranayama, followed by yoga postures called asanas, and the sequence will be finished with savasana pose. In this pose, guided meditations will be performed on subjects such as body awareness and self-compassion.
Study: NCT06119399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Exercise
Description: Diaphragmatic breathing exercise will be taught by placing the subject comfortably positioned with either therapist or the patient's hand directed over the abdominal area and instructing the subjects to focus on an outward movement of the abdominal area throughout inspiration and an inward movement of the abdominal area during expiration. (4 sets, and as each set had 4 complete breathing breaks, these exercises will be conducted for 3 days a week for 6 weeks)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pursed Lip Breathing Exercise
Description: Pursed lip breathing exercises will be performed by necessitating the subjects to inhale through their nose and then exhaling slowly for a period of 4-6 s by pursing the lips

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doming of the diaphragm
Description: * The physiotherapist places the thumbs just inferior to the patient's lower costal margin and xiphoid process with the thumbs pointing cephalad.~* The patient is instructed to take a deep breath and exhale. On exhalation, the physiotherapist's thumbs follow the diaphragm, which permits the thumbs to move posteriorly.~* The patient is instructed to inhale, and the physiotherapist gently resists this motion.~* The patient is instructed to exhale, and the physiotherapist gently follows this motion posteriorly and cephalad, as the thumbs are now beneath the costal margin and xiphoid process.~* The patient inhales as the physiotherapist maintains pressure on the upper abdomen and then, on repeated exhalation, encourages further cephalad excursion.~* This procedure is repeated for three to five respiratory cycles until the diaphragm domes easily at the end of exhalation.
Study: NCT06712082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07264660
Description: PF-07264660 solution for injection (single use only)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for injection (single use only)
Study: NCT06711822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shockplus-10
Description: Patients with coronary artery calcification who are planned to undergo PCI and are deemed in need of ShockPulse-10 treatment by their physicians
Study: NCT06714266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib 240mg/m2, intravenous infusion for 30 minutes, completed within 4 hours before daily chemotherapy; Chemotherapy regimen: FP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; 5-FU 1000 mg/m2, intravenous infusion, D1-4; Q3W); TP regimen (cisplatin/carboplatin +5-FU regimen: cisplatin 75mg/m2 D1, D2, D3 or carboplatin AUC 5, intravenous infusion D1; Docetaxel 75mg/m2 or albumin paclitaxel 200mg, IV infusion, D1, 8; Q3W). The specific dose can be adjusted according to the situation.~Immunotherapy: Pembrolizumab 200mg q2w Targeted therapy: cetuximab (400mg/m2 qw 250mg/m2 qw) Some patients can be treated with maintenance therapy, and the treatment regimen is immunotherapy or targeted therapy combined with Trilaciclib
Study: NCT06711900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKB264
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin or cisplatin
Description: IV Infusion
Study: NCT04575883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedBIKE HIIT
Description: Participants will complete a high intensity interval training exercise program 3 times a week for 12 weeks (36 sessions total)
Study: NCT06712693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Audeo Infinio Hearing Aid
Description: Receiver-In-Canal hearing aid type that is coupled with either a custom earmold or a dome.
Study: NCT06708962

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's mobilization
Description: Mulligan mobilization isthe concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroid injection for rotator cuff tendinopathy
Description: corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: corticosteroid injection for rotator cuff tendinopathy
Description: corticosteroid injection for rotator cuff helps resolving inflammation which occur for paraplegic patients from overuse of the crutches
Study: NCT06713486

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed pressure obtained in the polysomnography for 28 days
Description: home nocturnal therapy either at the fixed pressure obtained in the polysomnography for 28 days

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode
Description: dynamic pressure in Dreamstation AVAPS-AAM PhilipsRespironic® mode (program B) for 28 days, using the apnea threshold obtained in the titration as the maximum EPAP pressure and adjusting the support pressure for inferred Vt to 8 ml/kg of ideal body weight. After the first 28 days, a polysomnography will be performed under therapy with the device, and the next morning, cycle ergometry will be conducted.
Study: NCT06712563

Intervention type: DRUG
Intervention: Budesonide/glycopyrrolate/formoterol fumarate
Description: Budesonide/glycopyrrolate/formoterol fumarate (BGF) is a triple fixed-dose combination therapy for adults with moderate to severe COPD who are not adequately treated by a combination of inhaled corticosteroids and long-acting beta-agonist (LABA), or LABA and long-acting muscarinic-antagonist
Study: NCT06713421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone+Pronase
Description: Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone+Pronase
Description: Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder and 20,000 IU pronase granules combined with 1 g NaHCO3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethicone
Description: Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dimethicone
Description: Approximately 15-20 minutes before EGD, patients orally receive 50mL of warm water containing 5g dimethicone powder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: with Postural Exercise
Description: After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: with Postural Exercise
Description: After the premedication is administered orally approximately 15-20 minutes before EGD, patients are asked to take a 3-minute postural exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: without Postural Exercise.
Description: After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: without Postural Exercise.
Description: After the premedication is administered orally approximately 15-20 minutes before EGD, patients sit quietly awaiting examination.
Study: NCT06711549

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Posterior Superior Plane Intercostal Plane block
Description: Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus posterior superior plane and the ribs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plane block
Description: Under ultrasound guidance; local anesthetic will be injected in the plane between the posterior aspect of the serratus anterior and the external intercostal muscles and ribs
Study: NCT05967403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the conventional closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol administration rate will be controlled by a feedback loop facilitated by BIS monitoring using the hermetic closed loop anaesthesia delivery system (CLADS). A BIS value of 50 will be used as the target point for induction and maintenance of anaesthesia.
Study: NCT06411132

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT04423588

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: dexlansoprazole serum concentration
Description: 6 blood samples are collected at fixed time Points after oral Administration of 1 dose of dexilant at regular patients visits preoperatively and 3 and 6 months post-surgery.
Study: NCT06119399

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program for chronic neck pain
Description: Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise program for chronic neck pain
Description: Patients will perform three repetitions of stretching exercises for neck flexor, extensor, lateral flexor, and rotator for 30 seconds as warm-up and cool-down exercises, to relieve tension on each side of the neck.~Then cranio-cervical flexion exercise will be started using feedback from an air-filled pressure sensor placed behind the neck. Subjects will lay in the crook lying position. The pressure biofeedback unit will be placed below the occiput and inflated up to a baseline pressure of 20 mmHg. The subjects will be instructed to perform head-nodding action to progressively target 5 pressure levels (hold 10 seconds with brief rest periods between each contraction 3-5 seconds). This includes 3 sets in a session for 10 repetitions each with 2 minutes of rest between sets and 3days a week for 6 weeks.
Study: NCT04423588

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: upper endoscopy
Description: 6 and 12 months after surgery the occurrence of marginal ulcers in the same Patient Group is examined by upper endoscopy. The 12-month endoscopy is part of the Routine postoperative diagnosis, the 6-month endoscopy is for study purpose.
Study: NCT04857944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEA program (Improving depressive symptoms through personalised exercise and activation)
Description: The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IDEA program (Improving depressive symptoms through personalised exercise and activation)
Description: The program will consist of six 90-minute group sessions composed of four to six participants. These short intervention sessions will be distributed in one month, with a frequency of once or twice a week depending on the week of the program. Of the six sessions, two will be exercise-oriented and will include on-site practice. The remaining four sessions will include definitions of depressive symptomatology, the relationship between depression and having an active lifestyle, motivation and barriers towards exercise, and maintenance strategies.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: IDEApp
Description: An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDEApp
Description: An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IDEApp
Description: An ad-hoc app (IDEApp) combined with a fitness tracker to register and store participants' physical activity, exercise compliance, and sleep patterns. The app will deliver motivational or awareness messages when the fitness tracker detects non-compliance with the exercise prescription, physical activity decreases, or altered sleep patterns.